Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEERLESS II: FlowTriever vs. Anticoagulation in Pulmonary Embolism
NCT06055920Completed
- Sponsor
- Inari Medical
- Start
- Nov 2023
- Primary completion
- Jul 2026
- Countries
- 8
01
Overview
Randomised, open-label trial in pulmonary embolism (PE) (2 arms), sponsored by Inari Medical. Primary endpoint: Composite clinical endpoint constructed as a win ratio at 30 days. Started Nov 2023; status: completed.
02
Conditions
pulmonary embolism (PE)
Beyond the preview
Go deeper on NCT06055920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06055920.